Drug Trial Radar · NCT05900986
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jul 14, 2023
Primary completion
Oct 6, 2025
Study completion May 6, 2026
Sponsor
- Lead sponsor
- Integro TheranosticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.
Conditions
- Breast Cancer
- DCIS
- Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kgDrug
The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
LS301-IT 0.05 mg/kgDrug
Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
LS301-IT 0.075 mg/kgDrug
Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
LS301-IT 0.1 mg/kgDrug
Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 30 days
- PharmacodynamicsTime frame: during surgery
- PharmacodynamicsTime frame: During surgery
- CmaxTime frame: 24 hours
- AUCinfTime frame: 24 hours
- AUClastTime frame: 24 hours
- TmaxTime frame: 24 hours
- t1/2Time frame: 24 hours
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Integro Theranostics Research Site #2
Scottsdale, Arizona
Integro Theranostics Research Site #12
Washington D.C., District of Columbia
Integro Theranostics Research Site #9
Weston, Florida
Integro Theranostics Research Site #6
The Bronx, New York
Integro Theranostics Clinical Research Site #8
Winston-Salem, North Carolina
Integro Theranostics Research Site #10
Cleveland, Ohio
Integro Theranostics Research Site #5
Philadelphia, Pennsylvania
Integro Theranostics Research Site #3
Dallas, Texas
Integro Theronostics Research Site #1
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.